-
Identifying Genetic Factors Influencing the Development of Anti-Drug Antibodies in Inflammatory Bowel Disease: A Scoping Review
16 Dec 2025 20:19 GMT
… monoclonal antibodies produced by biotechnological methods), with no other … types (eg, clinical trials, cohort studies, case-controls … treated with anti-TNF drugs. Medicina. 2025;61(1): … treated by combination treatment with infliximab and azathioprine. Aliment …
-
Management and Treatment of Perianal Fistulizing Crohn’s Disease
12 Dec 2025 16:33 GMT
… tract.16
Medical Treatment
Antibiotic Therapy
Before the landmark infliximab trial in PFCD … Certolizumab
Although randomized controlled trials specifically evaluating adalimumab and … submitted to the Food and Drug Administration (FDA) for approval. This, …
-
Celltrion’s Autoimmune Therapy “Avtozma” Listed as Preferred Drug by Major U.S. PBM Synergie Collective
12 Dec 2025 06:35 GMT
… announced that its autoimmune disease treatment “Avtozma” (tocilizumab), currently marketed in … has been designated a “preferred” drug across all public and private … product “Zymfentra,” the only subcutaneous infliximab worldwide, is already listed across …
-
New Crohn’s Guideline Stresses Early Use of Advanced Drugs
11 Dec 2025 10:43 GMT
… using a higher-efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab … monotherapy over no treatment for maintenance of … but prospective clinical trial data supporting this … said. Several ongoing clinical trials are assessing this endpoint …
-
Adalimumab, Infliximab and Etanercept Biosimilars Market to Reach USD $7.34 Billion by 2029 at 10.3% CAGR
09 Dec 2025 15:30 GMT
… and Remicade.
Who Are The Key Players In The Adalimumab, Infliximab and … Samsung Bioepis (Samsung Biologics)
• Hetero Drugs Limited
• Fresenius Kabi AG
• Boehringer … , a German pharmaceutical and medical technology company, received FDA approval for its …
-
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
03 Dec 2025 02:14 GMT
… . Food and Drug Administration (FDA)-approved anti- …
Potential Medication Error Related to Emergency Treatment of … biosimilar. Our global pharmaceutical portfolio addresses a … ophthalmology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab- …
-
‘My Crohn’s got so bad, I vomited faeces – and I’m still battling for the right treatment’
02 Dec 2025 09:59 GMT
… , neither she nor her doctors understood the cause.
Crohn … urgently after mealtimes, led medical professionals to assume she … disease.
She was prescribed infliximab and azathioprine, and put … unbearable pain.
“Since starting treatment, things have actually got …
-
'If doctors sent me home like they tried to, I would have died'
02 Dec 2025 09:32 GMT
… urgently after meals, led medical professionals to initially suspect … far from over.
Doctors prescribed her infliximab and azathioprine, placing … trying a variety of medications in the hopes that … answers
"Since starting treatment, things have actually got …
-
Diversity of Multi-Drug Resistance Genes in Escherichia coli Isolated from Poultry in Southern Togo
27 Nov 2025 10:28 GMT
… outlined in the document stating that at least 30% … human medicine, colistin has long been excluded from treatment protocols … Naturelles, École doctorale ED589. Thèse de Doctorat de l’Université … predictor of relapse after infliximab withdrawal in Crohn’s …
-
Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
26 Nov 2025 08:14 GMT
… colitis following treatment with an infliximab product administered … . Our global pharmaceutical portfolio addresses a … drugs to push the boundaries of scientific innovation and deliver quality medicines … unique heritage in biotechnology, supply chain …
About
© 1995-2025